Control of Bone Homeostasis by the Wnt Inhibitor Sclerostin

[1]  H. Morris,et al.  Early response of the human SOST gene to stimulation by 1α,25-dihydroxyvitamin D3 , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  S. Ruiz-Gaspà,et al.  Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Yi-Xian Qin,et al.  Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse. , 2016, Bone.

[4]  A. Grauer,et al.  OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study , 2016 .

[5]  B. Dawson,et al.  Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap–/– Mice, a Model of Recessive Osteogenesis Imperfecta , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  F. Rauch,et al.  Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model? , 2016, Clinical orthopaedics and related research.

[7]  Jacques P. Brown,et al.  Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study , 2016 .

[8]  Igor Fijalkowski,et al.  A Novel Domain‐Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  C. Hartmann,et al.  Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction , 2016, Science Translational Medicine.

[10]  William R. Lloyd,et al.  Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age. , 2016, Bone.

[11]  Yudong D. He,et al.  Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. , 2016, Bone.

[12]  Liangliang Xu,et al.  Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats , 2016, Calcified Tissue International.

[13]  Alaa M Althubaiti,et al.  Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry , 2016, Journal of bone metabolism.

[14]  P. Vestergaard,et al.  Differences in biochemical bone markers by diabetes type and the impact of glucose. , 2016, Bone.

[15]  P. Vestergaard,et al.  Bone Structure and Predictors of Fracture in Type 1 and Type 2 Diabetes. , 2016, The Journal of clinical endocrinology and metabolism.

[16]  Xu Cao,et al.  Lipoprotein receptor–related protein 6 is required for parathyroid hormone–induced Sost suppression , 2016, Annals of the New York Academy of Sciences.

[17]  C. Graeff,et al.  Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. , 2015, Bone.

[18]  Jian Q. Feng,et al.  Sclerostin Antibody Preserves the Morphology and Structure of Osteocytes and Blocks the Severe Skeletal Deterioration After Motor‐Complete Spinal Cord Injury in Rats , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Halil Bayram,et al.  Serum Sclerostin Levels in Newborns Born to Mothers With Vitamin D Deficiency , 2015, Journal of Investigative Medicine.

[20]  C. Foresta,et al.  Regulation of Sclerostin Production in Human Male Osteocytes by Androgens: Experimental and Clinical Evidence. , 2015, Endocrinology.

[21]  G. Loots,et al.  1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion , 2015, Molecular and Cellular Endocrinology.

[22]  R. Recker,et al.  The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  Yudong D. He,et al.  Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  C. Jenkinson,et al.  Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism , 2015, Diabetes Care.

[25]  Marc N. Wein,et al.  The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro* , 2015, The Journal of Biological Chemistry.

[26]  S. Borst,et al.  Sclerostin Inhibition Prevents Spinal Cord Injury‐Induced Cancellous Bone Loss , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  John G Doench,et al.  HDAC5 Controls MEF2C‐Driven Sclerostin Expression in Osteocytes , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  M. Pazianas.  Anabolic effects of PTH and the ‘anabolic window’ , 2015, Trends in Endocrinology & Metabolism.

[29]  Joseph D. Salemi,et al.  Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. , 2015, Bone.

[30]  R. Recker,et al.  A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  Bjarni V. Halldórsson,et al.  Methylation of Bone SOST, Its mRNA, and Serum Sclerostin Levels Correlate Strongly With Fracture Risk in Postmenopausal Women , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  M. McDonald,et al.  Endochondral fracture healing with external fixation in the Sost knockout mouse results in earlier fibrocartilage callus removal and increased bone volume fraction and strength. , 2015, Bone.

[33]  V. Fabiano,et al.  Sclerostin and DKK-1: two important regulators of bone metabolism in HIV-infected youths , 2015, Endocrine.

[34]  R. Harnish,et al.  Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures , 2015, Osteoporosis International.

[35]  B. Dawson-Hughes,et al.  The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  P. Kostenuik,et al.  Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. , 2014, Bone.

[37]  P. Kostenuik,et al.  Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. , 2014, Endocrinology.

[38]  Frank Rauch,et al.  Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. , 2014, Bone.

[39]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[40]  T. Fehr,et al.  Sclerostin Blood Levels Before and After Kidney Transplantation , 2014, Kidney and Blood Pressure Research.

[41]  Hansjoerg Keller,et al.  Class I and IIa Histone Deacetylases Have Opposite Effects on Sclerostin Gene Regulation , 2014, Journal of Biological Chemistry.

[42]  H. Malluche,et al.  Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[43]  H. Ke,et al.  Tissue‐Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  Ning Leng,et al.  The osteoblast to osteocyte transition: epigenetic changes and response to the vitamin D3 hormone. , 2014, Molecular endocrinology.

[45]  Joseph D. Salemi,et al.  Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength , 2014, Osteoporosis International.

[46]  L. Hofbauer,et al.  Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus , 2014, Clinical endocrinology.

[47]  J. Klein-Nulend,et al.  Nitric Oxide is Involved in the Down-regulation of SOST Expression Induced by Mechanical Loading , 2014, Calcified Tissue International.

[48]  M. Stolina,et al.  Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model , 2014, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[49]  A. Kivitz,et al.  Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double‐blind, placebo‐controlled study , 2014, Journal of clinical pharmacology.

[50]  S. Khosla,et al.  Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. , 2014, Bone.

[51]  Cesar Libanati,et al.  Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.

[52]  R. Kumar,et al.  Sclerostin deficient mice rapidly heal bone defects by activating β-catenin and increasing intramembranous ossification. , 2013, Biochemical and biophysical research communications.

[53]  L. Schurgers,et al.  Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study , 2013, BMC Nephrology.

[54]  L. Plotkin,et al.  Resorption Controls Bone Anabolism Driven by Parathyroid Hormone (PTH) Receptor Signaling in Osteocytes* , 2013, The Journal of Biological Chemistry.

[55]  S. Khosla,et al.  Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast‐mediated stimulation of mineralization , 2013, Journal of cellular biochemistry.

[56]  T. Sugimoto,et al.  Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. , 2013, The Journal of clinical endocrinology and metabolism.

[57]  M. Stolina,et al.  Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis , 2013, Annals of the rheumatic diseases.

[58]  D. Fouque,et al.  The relation between renal function and serum sclerostin in adult patients with CKD. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[59]  E. González‐Reimers,et al.  Serum sclerostin in alcoholics: a pilot study. , 2013, Alcohol and alcoholism.

[60]  M. Bouxsein,et al.  Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[61]  T. Craig,et al.  Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium , 2013, Proceedings of the National Academy of Sciences.

[62]  M. Heer,et al.  Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men. , 2013, Journal of musculoskeletal & neuronal interactions.

[63]  M. Genovese,et al.  Effects of sclerostin antibody on healing of a non‐critical size femoral bone defect , 2013, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[64]  P. Dechow,et al.  Repression of osteocyte Wnt/β‐catenin signaling is an early event in the progression of renal osteodystrophy , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[65]  J. Kanis,et al.  FRAX underestimates fracture risk in patients with diabetes , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[66]  Lynda F. Bonewald,et al.  Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway , 2011, PloS one.

[67]  E. Yu,et al.  Acute decline in serum sclerostin in response to PTH infusion in healthy men. , 2011, The Journal of clinical endocrinology and metabolism.

[68]  S. Khosla,et al.  Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. , 2011, Bone.

[69]  J. Elliott,et al.  Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected Patients , 2011, Journal of acquired immune deficiency syndromes.

[70]  J. Millán,et al.  The Appearance and Modulation of Osteocyte Marker Expression during Calcification of Vascular Smooth Muscle Cells , 2011, PloS one.

[71]  A. Branscum,et al.  Sclerostin and Dickkopf-1 in renal osteodystrophy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[72]  R. McCall,et al.  Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. , 2011, The Journal of clinical endocrinology and metabolism.

[73]  W. Jee,et al.  Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. , 2011, Bone.

[74]  P. Kostenuik,et al.  Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[75]  Qing Chen,et al.  Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[76]  P. Kostenuik,et al.  Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[77]  E. Jones,et al.  Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies , 2008, Mechanisms of Ageing and Development.

[78]  Matthew R Allen,et al.  Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin* , 2008, Journal of Biological Chemistry.

[79]  F. Natt,et al.  Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[80]  M. Joy,et al.  Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment , 2007, Journal of managed care pharmacy : JMCP.

[81]  F. Glorieux,et al.  Risedronate in the treatment of mild pediatric osteogenesis imperfecta: A randomized placebo-controlled study , 2007 .

[82]  R. Jilka,et al.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. , 2005, Endocrinology.

[83]  M. Kneissel,et al.  SOST is a target gene for PTH in bone. , 2005, Bone.

[84]  Peng Liu,et al.  Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.

[85]  M. Karperien,et al.  Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist , 2004, The Journal of experimental medicine.

[86]  汪关煜.  Renal osteodystrophy , 2002 .

[87]  K. Lindpaintner,et al.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease , 2002, Journal of medical genetics.

[88]  A. Folsom,et al.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. , 2001, Diabetes care.

[89]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[90]  D. Galas,et al.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.

[91]  S. Larsson.  Anti-sclerostin - is there an indication? , 2016, Injury.

[92]  Zhang Chang-qing,et al.  Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats. , 2015, International immunopharmacology.

[93]  R. Ritchie,et al.  Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength , 2015, Osteoporosis International.

[94]  Y. Rhee,et al.  Effect of liver dysfunction on circulating sclerostin , 2013, Journal of Bone and Mineral Metabolism.

[95]  任培根.  Effects of Sclerostin Antibody on Healing of a Non-critical Size Femoral Bone Defect , 2012 .

[96]  Cycle Xxiii.  CIRCULATING SCLEROSTIN LEVELS AND BONE TURNOVER IN TYPE 1 AND TYPE 2 DIABETES , 2011 .

[97]  B. Clarke.  Regulation of Circulating Sclerostin Levels by Sex Steroids in Women and in Men , 2011 .

[98]  D. Fyhrie,et al.  Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. , 2009, Biorheology.